Skip to main content

Table 4 Treatment efficacy and adherence to therapy

From: Therapy of chronic hepatitis C in people who inject drugs: focus on adherence

  PWID group Control group p
SVR 12 99 (98%) 172 (98%) N. S.
 Lost to follow-up 2 (2.0%) 1 (0.6%)  
 Relapse 0 (0%) 4 (1.4%)  
SVR 24 89 (88.1%) 163 (92.1%) N. S.
 Lost to follow-up 10 (9.9%) 5 (2.8%)  
 Relapse 1 (1%) 9 (5.1%)  
 Reinfection 1 (1%) 0 (0%)  
SVR 12 according to adherence    N. S.
 100% adherent 69 (100%) 153 (95.6%)  
 Non-100% adherent 30 (93.8%) 15 (88.2%)  
Treatment termination on time 99 (98%) 169 (95.5%) N. S.
Premature treatment termination 0 (0%) 1 (0.6%) N. S.
Postponed treatment termination 2 (2.0%) 7 (4.0%) N. S.
Delay (days)
 Patient 1 3   
 Patient 2 3   
 Patient 3   2  
 Patient 4   1  
 Patient 5   1  
 Patient 6   1  
 Patient 7   7  
 Patient 8   2  
 Patient 9   2  
Missed doses (no. of patients)
 1 dose 0 3 N. S.
 2 doses 0 3  
 3 doses 2 0  
 7 doses 0 1  
Postponed visits (no. of patients) 29 (28.7%) 7 (4.0%) < 0.001
 1 visit 17 7  
 2 visits 8 0  
 3 visits 4 0  
Missed visits (no. of patients) 13 (12.9%) 6 (3.4%) 0.006
 1 visit 11 6  
 2 visits 2 0  
Lack of medication (no. of patients) 1 (1%) 2 (1.1%) N. S.
 Patient 1 (missed doses) 3   
 Patient 2 (missed doses)   2  
 Patient 3 (missed doses)   2  
Missed visit 12 weeks post-treatment (SVR 12) 2 (2%) 1 (0.6%) N. S.
Missed visit 24 weeks post-treatment (SVR 24) 11 (10.9%) 2 (1.1%) 0.004
  1. P value of < 0.05 was considered statistically significant and the results are displayed in bold
  2. PWID people who inject drugs group, SVR sustained virological response